Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders

Jeffrey L. Cummings (), Yadi Zhou, Alexandra Stone, Davis Cammann, Reina Tonegawa-Kuji, Jorge Fonseca and Feixiong Cheng
Additional contact information
Jeffrey L. Cummings: Las Vegas (UNLV)
Yadi Zhou: Cleveland
Alexandra Stone: Roseman University of Health Sciences
Davis Cammann: University of Nevada Las Vegas (UNLV)
Reina Tonegawa-Kuji: Cleveland
Jorge Fonseca: Las Vegas (UNLV)
Feixiong Cheng: Cleveland

Nature Communications, 2025, vol. 16, issue 1, 1-10

Abstract: Abstract Repurposed drugs provide a rich source of potential therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders (NDD). Repurposed drugs have information from non-clinical studies, phase 1 dosing, and safety and tolerability data collected with the original indication. Computational approaches, “omic” studies, drug databases, and electronic medical records help identify candidate therapies. Generic repurposed agents lack intellectual property protection and are rarely advanced to late-stage trials for AD/NDD. In this review we define repurposing, describe the advantages and challenges of repurposing, offer strategies for overcoming the obstacles, and describe the key contributions of repurposing to the drug development ecosystem.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-56690-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56690-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-56690-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().